Task 2026 NSCOR: CVD/Late CNS MCM Assessment: Combined Spaceflight Stressors
Last Published:  03/29/18 08:54:56 AM (Central)
Short Title: 2026 CVD/Late CNS biomarker & CM Val
Responsible HRP Element: Space Radiation
Collaborating Org(s):
Funding Status: Planned-Funded - Task expected to be within budget
Procurement Mechanism(s):
Solicited
Aims:
  • Aim 1 (CVD):  Validate efficacy of standard of care clinical protective measures in a combined stressor model with chronic mixed field exposures, evaluating for mitigation of radiation-induced CVD.

  • Aim 2 (CVD/CNS): Validate efficacy of cross-risk candidate radioprotective agents in a combined stressor model with chronic mixed field exposures, evaluating for mitigation of radiation-induced CVD and late CNS adverse outcomes.

  • Aim 3 (CVD, CNS):  Evaluate any potential antagonistic, synergistic, or additive effects across CVD protective measures and late CNS adverse outcomes.


Resources (None Listed)
Mappings
RiskRisk of Acute (In-flight) and Late Central Nervous System Effects from Radiation Exposure
GapCNS - 2: Does space radiation exposure elicit key events in adverse outcome pathways associated with neurological diseases? What are the key events or hallmarks, their time sequence and their associated biomarkers (in-flight or post-flight)?
GapCNS - 4: What are the most effective medical or dietary countermeasures to mitigate CNS risks? By what mechanisms are the countermeasures likely to work?
GapCNS - 6: How can new knowledge and data from molecular, cellular, tissue and animal models of late CNS risks or clinical human data be used to estimate late CNS risks to astronauts from GCR and SPE?
GapCNS - 8: Are there significant CNS risks from combined space radiation and other physiological or space flight factors, e.g., psychological (isolation and confinement), altered gravity (micro-gravity), stress, sleep deficiency, altered circadian rhythms, hypercapnea, altered immune, endocrine and metabolic function, or other?
You are here!Task2026 NSCOR: CVD/Late CNS MCM Assessment: Combined Spaceflight Stressors

RiskRisk of Cardiovascular Disease and Other Degenerative Tissue Effects From Radiation Exposure and Secondary Spaceflight Stressors
GapDegen - 2: What are the adverse outcome pathways associated with degenerative tissues changes in the cardiovascular, cerebrovascular, lens, immune, digestive, endocrine, and other tissue systems? What are the key events or hallmarks, their time sequence, and their associated biomarkers?
GapDegen - 3: What are the progression rates and latency periods for radiation-induced degenerative diseases, and how do progression rates depend on age, sex, radiation type, or other physiological or environmental factors?
GapDegen - 5: What quantitative procedures or theoretical models are needed to extrapolate molecular, cellular, animal results, or clinical human data to predict degenerative tissue risks in astronauts? How can human epidemiology data best support these procedures or models?
GapDegen - 6: What are the most effective medical or dietary countermeasures to mitigate degenerative tissue risks? Are there common pathways that will benefit multiple tissues?
You are here!Task2026 NSCOR: CVD/Late CNS MCM Assessment: Combined Spaceflight Stressors